Biora Therapeutics, Inc.
BIORDelisted Jun 4, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001580063
Biora Therapeutics, Inc. was delisted on Jun 4, 2025; its insiders filed their last Form 4 on Dec 16, 2024; 21 institutions reported holding it in 13F filings for Q3 2024, worth $6.13M in total; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Biora Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Biora Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Ferrell Jeffrey | Director, 10% Owner | 10,929,763Indirect | Dec 16, 2024 | 0 |
| Athyrium Opportunities Associates III GP LLC | Director, 10% Owner | 10,929,763Indirect | Dec 16, 2024 | 0 |
| Athyrium Funds GP Holdings LLC | Director, 10% Owner | 10,929,763Indirect | Dec 16, 2024 | 0 |
| Athyrium Opportunities Associates Co-Invest LLC | Director, 10% Owner | 10,929,763Indirect | Dec 16, 2024 | 0 |
| Athyrium Opportunities III Co-Invest 1 LP | Director, 10% Owner | 10,929,763Indirect | Dec 16, 2024 | 0 |
| Athyrium Opportunities 2020 LP | Director, 10% Owner | 10,929,763Indirect | Dec 16, 2024 | 0 |
| Athyrium Opportunities Associates III LP | Director, 10% Owner | 10,929,763Indirect | Dec 16, 2024 | 0 |
| Athyrium Opportunities III Acquisition 2 LP | Director, 10% Owner | 10,929,763Indirect | Dec 16, 2024 | 0 |
| Athyrium Opportunities III Acquisition LP | Director, 10% Owner | 10,929,763Indirect | Dec 16, 2024 | 0 |
| Neumann Clarke | See Remarks | 465,564 | Aug 16, 2024 | 0 |
| dEsparbes Eric | Chief Financial Officer | 575,832 | Aug 16, 2024 | 0 |
| Mohanty Aditya P. | Chief Executive Officer | 1,468,609 | Aug 16, 2024 | 0 |
| Powell Lynne | Director | 30,746 | Jun 6, 2024 | 0 |
| Kotzin Brian L. | Director | 30,746 | Jun 6, 2024 | 0 |
| Alter Jeffrey D. | Director | 31,546 | Jun 6, 2024 | 0 |
| Howe Jill Ann | Director | 31,916 | Jun 6, 2024 | 0 |
| Sarna Surbhi | Director | 0 | Jan 5, 2023 | 0 |
| Hashemi Hutan | Chief Compliance Officer | 28,495 | Feb 17, 2022 | 0 |
| Silvestry Damon | See Remarks | 291,499 | Nov 17, 2021 | 0 |
| Cooper Matthew T | General Manager, Diagnostics | 134,039 | Nov 17, 2021 | 0 |
| Stylli Harry | Chairman & CEO | 14,816,522 | Aug 17, 2021 | 0 |
| Seelye Troy | Chief Information Officer | 59,756 | Aug 9, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 14, 2022 (view filing)4:30 PM ET | Nov 9 | 5 days | Ferrell Jeffrey and 8 othersDirector, 10% Owner | PPurchase | +12.5M | – | – | +41.9%42.4M after | |
| Nov 14, 2022 (view filing)4:30 PM ET | Nov 9 | 5 days | Ferrell Jeffrey and 8 othersDirector, 10% Owner | PPurchase | +12.5M | – | – | –12.5M after | Derivative |
| Jul 5, 2022 (view filing) | Jul 5 | Same day | Sarna SurbhiDirector | SSale | −7.52K | $0.61 | −$4.59K | −4.8%148.8K after |